Reckoning With Racism in Nursing: Towards Structural Transformation and Epistemic Justice
Click on the article title to read more.
Related Articles
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
What’s new? Patients who have metastatic renal cell carcinoma with sarcomatoid features (sRCC) have a very poor prognosis. Here, the authors describe the clinical characteristics…
Outgoing QICN chief warns of new threat to community nursing | Nursing Times
Read an interview with well-known community nursing leader Dr Crystal Oldman, who is retiring in July after 45 years in nursing.
When a “Thinking of You” Card Isn’t the Right Support for a Patient
Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.
CAR T Vision
By 2030, CAR T Vision aims to double the number of eligible patients treated with CAR T-cell therapy by expanding access across Europe and globally.
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
Computational systems biology approaches to cellular aging—Integrating network maps and dynamical models
Cellular aging is a multifaceted complex process. Many genes and factors have been identified that regulate cellular aging. However, how these genes and factors interact…
I’m a Survivor: The Day I Finally Believed It
I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not…
Free professional support for anyone affected by cancer
CancerCare is a national nonprofit organization providing free, professional support services for anyone affected by cancer.
The Person Behind Their Diagnosis: Understanding the Patient
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.